Company intelligence / Profile preview

Qana Therapeutics

Austin, Texas, United Statesqanatx.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Qana Therapeutics is developing a novel, metabolically-targeted therapy for adrenocortical carcinoma using proprietary targeted delivery technologies. The lead program is supported by an NIH/NCI Innovative Concept Award and is focused on addressing high unmet need in metastatic ACC, which has poor survival rates. No clinical results have been published yet; the program appears to be preclinical or at an early translational stage as of 2024.

Therapeutic areas: Oncology
Modalities: Small moleculeTargeted delivery technology
Industry: Biotech

Drug pipeline

1 asset

Myr5A

Preclinical

Partnerships

National Cancer Institute / National Institutes of Health SBIR funding partnership/support

Beyond the preview

Go deeper on Qana Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qana Therapeutics.